Mindmed announces publication of study comparing the acute effects of lysergic acid diethylamide and psilocybin in healthy subjects

New york, march 2, 2022 /prnewswire/ -- mind medicine (mindmed) inc. (nasdaq: mnmd), (neo: mmed), a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies for the treatment of brain-based disorders, today announced the peer-reviewed publication of a study directly comparing the acute effects of lysergic acid diethylamide (lsd) and psilocybin in healthy subjects. the data, published in neuropsychopharmacology and titled, " direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects ", demonstrates that the key differences between lsd and psilocybin are dose-dependent rather than substance-dependent.
MNMD Ratings Summary
MNMD Quant Ranking